STOCK TITAN

CNTA Form 144: Proposed 12k-share insider sale valued at $168,218

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (NASDAQ: CNTA) has submitted a Form 144 notifying the SEC of a proposed sale of 12,000 common shares by an insider through UBS Financial Services on 24 June 2025. The estimated aggregate market value is $168,218.40, implying a per-share price of roughly $14.02. The filing states that 133,618,774 shares are outstanding, meaning the planned sale represents less than 0.01 % of total shares. The seller acquired the shares the same day via a cash-settled stock-option exercise.

The insider previously sold a combined 6,000 shares over the past three months for total proceeds of $84,012.01. No additional operational or financial data were disclosed, and the signatory affirms awareness of no undisclosed material adverse information. Given the modest size relative to the float and the routine nature of Form 144 notices, the event is unlikely to materially affect Centessa’s fundamentals or valuation.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Minor insider sale; negligible ownership impact; neutral market effect.

The Form 144 reveals an insider’s intent to sell 12,000 CNTA shares, equal to roughly 0.009 % of the company’s outstanding equity. Past 90-day sales totaled another 6,000 shares, suggesting a gradual, modest liquidation pattern rather than aggressive dumping. Because the shares were obtained via option exercise on the same day, the transaction appears to be routine diversification or tax-related liquidity. No 10b5-1 plan date was disclosed, but the attestation of no undisclosed adverse information mitigates governance concerns. Overall, the filing is informational with neutral to immaterial financial impact for investors.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What SEC document did Centessa (CNTA) file?

Form 144—a notice of proposed insider sale of restricted or control securities.

How many CNTA shares are planned for sale?

The insider intends to sell 12,000 common shares.

What is the estimated value of the planned insider sale?

Approximately $168,218.40, based on the filing’s market value estimate.

When is the approximate sale date for these shares?

The filing lists 24 June 2025 as the expected sale date.

How significant is the sale relative to shares outstanding?

It equals less than 0.01 % of the 133,618,774 shares outstanding, a negligible amount.

Has the insider sold CNTA stock recently?

Yes; over the past 3 months the same insider sold 6,000 shares for gross proceeds of $84,012.01.
Centessa Pharmaceuticals Plc

NASDAQ:CNTA

CNTA Rankings

CNTA Latest News

CNTA Latest SEC Filings

CNTA Stock Data

3.35B
133.70M
0.49%
93.69%
3.93%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
ALTRINCHAM, CHESHIRE